Cilostazol - CAS 73963-72-1
Catalog number: 73963-72-1
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C20H27N5O2
Molecular Weight:
369.46
COA:
Inquire
Targets:
Phosphodiesterase (PDE)
Description:
Cilostazol is a potent cyclic nucleotide phosphodiesterase type 3 (PDE3) inhibitor with IC50 of 0.2 μM and inhibitor of adenosine uptake.
Purity:
>98%
Synonyms:
AT2266; CI919; Pd107779; NSC629661; AT 2266; CI 919; Pd 107779; NSC 629661; AT-2266; CI-919; Pd-107779; NSC-629661
MSDS:
Inquire
InChIKey:
RRGUKTPIGVIEKM-UHFFFAOYSA-N
InChI:
InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
Canonical SMILES:
C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4
1.The use of cilostazol in patients with peripheral arterial disease: results of a national physician survey.
DE Donato G1, Setacci F, Galzerano G, Mele A, Ruzz U, Setacci C. J Cardiovasc Surg (Torino). 2016 Apr 1. [Epub ahead of print]
BACKGROUND: Although international guidelines recommend cilostazol as first-line therapy for peripheral arterial disease (PAD ) because it improves the symptoms and quality of life, it remains an underused agent for amputation-free survival. The objective of this study is to evaluate the practice among Italian physicians of the use of cilostazol in patients suffering from peripheral arterial disease (PAD).
2.The Effect of High Dose Cilostazol and Rosuvastatin on Periprocedural Myocardial Injury in Patients with Elective Percutaneous Coronary Intervention.
H A1, N E1, S A1, S C1, K D1, C A1, E T1, A T1, O C Y1, M G2, T B1, M M1. Zhonghua Minguo Xin Zang Xue Hui Za Zhi. 2015 Jul;31(4):292-300.
BACKGROUND: The aim of our study was to assess the effect of pretreatment with cilostazol and rosuvastatin combination before elective percutaneous coronary intervention (PCI) on peri-procedural myocardial injury (PPMIJ).
3.Effect of Cilostazol on Cerebral Vasospasm and Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage: A Randomized, Double-Blind, Placebo-Controlled Trial.
Matsuda N1, Naraoka M, Ohkuma H, Shimamura N, Ito K, Asano K, Hasegawa S, Takemura A. Cerebrovasc Dis. 2016;42(1-2):97-105. doi: 10.1159/000445509. Epub 2016 Apr 13.
BACKGROUND: Several clinical studies have indicated the efficacy of cilostazol, a selective inhibitor of phosphodiesterase 3, in preventing cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH). They were not double-blinded trial resulting in disunited results on assessment of end points among the studies. The randomized, double-blind, placebo-controlled study was performed to assess the effectiveness of cilostazol on cerebral vasospasm.
4.Synergistic Effects of Cilostazol and Probucol on ER Stress-Induced Hepatic Steatosis via Heme Oxygenase-1-Dependent Activation of Mitochondrial Biogenesis.
Chen Y1, Pandiri I1, Joe Y1, Kim HJ1, Kim SK1, Park J1, Ryu J2, Cho GJ2, Park JW1, Ryter SW3, Chung HT1. Oxid Med Cell Longev. 2016;2016:3949813. doi: 10.1155/2016/3949813. Epub 2016 Jan 6.
The selective type-3 phosphodiesterase inhibitor cilostazol and the antihyperlipidemic agent probucol have antioxidative, anti-inflammatory, and antiatherogenic properties. Moreover, cilostazol and probucol can regulate mitochondrial biogenesis. However, the combinatorial effect of cilostazol and probucol on mitochondrial biogenesis remains unknown. Endoplasmic reticulum (ER) stress is a well-known causative factor of nonalcoholic fatty liver disease (NAFLD) which can impair mitochondrial function in hepatocytes. Here, we investigated the synergistic effects of cilostazol and probucol on mitochondrial biogenesis and ER stress-induced hepatic steatosis. A synergistic effect of cilostazol and probucol on HO-1 and mitochondrial biogenesis gene expression was found in human hepatocellular carcinoma cells (HepG2) and murine primary hepatocytes. Furthermore, in an animal model of ER stress involving tunicamycin, combinatorial treatment with cilostazol and probucol significantly increased the expression of HO-1 and mitochondrial biogenesis-related genes and proteins, whereas it downregulated serum ALT, eIF2 phosphorylation, and CHOP expression, as well as the lipogenesis-related genes SREBP-1c and FAS.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Phosphodiesterase (PDE) Products


CAS 317-34-0 Aminophylline

Aminophylline
(CAS: 317-34-0)

Aminophylline is a competitive nonselective phosphodiesterase inhibitor with an IC50 of 0.12 mM and also a nonselective adenosine receptor antagonist.

CAS 99519-84-3 L-651,582

L-651,582
(CAS: 99519-84-3)

L-651,582 is a novel inhibitor of both cAMP-phosphodiesterases and GMP-phosphodiesterases. It is also an orally active calcium channel blocker. It prevents oxid...

CAS 224157-99-7 Sch59498

Sch59498
(CAS: 224157-99-7)

Sch59498 is a potent inhibitor of phosphodiesterase 1c (Pde1c) with antihypertensive and antiplatelet effect.

CAS 78415-72-2 Milrinone

Milrinone
(CAS: 78415-72-2)

Milrinone is a phosphodiesterase 3 (PDE3) inhibitor with vasodilator properties, used to increase the heart's contractility. It increases erythrocyte cAMP activ...

CAS 115344-47-3 Siguazodan

Siguazodan
(CAS: 115344-47-3)

Siguazodan is a selective phosphodiesterase 3 (PDE3) inhibitor (IC50 = 117 nM). Siguazodan acts as a potent vasodilator.

CAS 2066488-39-7 (S)-C33

(S)-C33
(CAS: 2066488-39-7)

(S)-C33 is a potent and selective PDE9 inhibitor (IC50 = 11 nM).

CAS 152633-54-0 Win-62005

Win-62005
(CAS: 152633-54-0)

Win-62005 competitively and selectively inhibits cyclic GMP-inhibitable low Km cyclic AMP phosphodiesterase (PDE III) from rat heart and canine aorta (Kis= 25 a...

CAS 73963-72-1 Cilostazol

Cilostazol
(CAS: 73963-72-1)

Cilostazol is a potent cyclic nucleotide phosphodiesterase type 3 (PDE3) inhibitor with IC50 of 0.2 μM and inhibitor of adenosine uptake.

Chemical Structure

CAS 73963-72-1 Cilostazol

Quick Inquiry

Verification code

Featured Items